SEHK:1349Pharmaceuticals
Shanghai Fudan-Zhangjiang (SEHK:1349) Losses Widen 29.4% Annually, Challenging Turnaround Hopes
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Ltd (SEHK:1349) reported ongoing losses, with net losses deepening at a 29.4% annual rate over the past five years and no visible turnaround in profit margins this year. The company’s Price-to-Sales ratio stands at 4.4x, higher than the Hong Kong Pharmaceuticals industry average of 2.5x. However, it is more attractive versus peers at 6.6x. Shares are trading at HK$3.27, significantly under an indicated fair value of HK$22.18. Despite weak earnings...